Detalhe da pesquisa
1.
Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer.
Nature
; 615(7950): 168-174, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36813961
2.
Virus-induced senescence is a driver and therapeutic target in COVID-19.
Nature
; 599(7884): 283-289, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34517409
3.
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
J Hepatol
; 80(3): 431-442, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37972660
4.
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey.
Blood
; 140(26): 2773-2787, 2022 12 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36126318
5.
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry.
Haematologica
; 2024 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38572549
6.
Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma.
Clin Chem
; 69(3): 295-307, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36644936
7.
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
Hepatology
; 76(4): 1000-1012, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35313048
8.
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.
Liver Int
; 42(11): 2538-2547, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35986902
9.
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey.
Infection
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38388854
10.
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report.
Am J Hematol
; 97(8): E312-E317, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35702878
11.
The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.
Leuk Lymphoma
; 65(2): 199-208, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37966980
12.
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.
EClinicalMedicine
; 71: 102553, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38533127
13.
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
Hepatol Int
; 17(4): 904-914, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37005953
14.
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study.
Hepatol Commun
; 7(11)2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37889520
15.
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry.
Ther Adv Hematol
; 14: 20406207231154706, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36923264
16.
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry.
Front Immunol
; 14: 1125030, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36911708
17.
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.
J Hematol Oncol
; 16(1): 32, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37005697
18.
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey.
Blood Adv
; 7(11): 2645-2655, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37058479
19.
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry.
EClinicalMedicine
; 58: 101939, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37041967
20.
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.
Int J Antimicrob Agents
; 62(4): 106952, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37582478